AGL 38.41 Decreased By ▼ -0.07 (-0.18%)
AIRLINK 202.99 Decreased By ▼ -0.03 (-0.01%)
BOP 10.05 Decreased By ▼ -0.12 (-1.18%)
CNERGY 6.44 Decreased By ▼ -0.10 (-1.53%)
DCL 9.45 Decreased By ▼ -0.13 (-1.36%)
DFML 39.70 Decreased By ▼ -0.32 (-0.8%)
DGKC 98.90 Increased By ▲ 0.82 (0.84%)
FCCL 35.45 Increased By ▲ 0.49 (1.4%)
FFBL 88.44 Increased By ▲ 2.01 (2.33%)
FFL 13.85 Decreased By ▼ -0.05 (-0.36%)
HUBC 130.65 Decreased By ▼ -0.92 (-0.7%)
HUMNL 13.95 Decreased By ▼ -0.07 (-0.5%)
KEL 5.50 Decreased By ▼ -0.11 (-1.96%)
KOSM 7.41 Increased By ▲ 0.14 (1.93%)
MLCF 46.10 Increased By ▲ 0.51 (1.12%)
NBP 61.73 Decreased By ▼ -4.65 (-7.01%)
OGDC 220.01 Decreased By ▼ -0.75 (-0.34%)
PAEL 39.20 Increased By ▲ 0.72 (1.87%)
PIBTL 8.78 Decreased By ▼ -0.13 (-1.46%)
PPL 197.50 Decreased By ▼ -0.38 (-0.19%)
PRL 39.35 Increased By ▲ 0.32 (0.82%)
PTC 25.72 Increased By ▲ 0.25 (0.98%)
SEARL 106.81 Increased By ▲ 3.76 (3.65%)
TELE 8.91 Decreased By ▼ -0.11 (-1.22%)
TOMCL 36.45 Increased By ▲ 0.04 (0.11%)
TPLP 13.90 Increased By ▲ 0.15 (1.09%)
TREET 24.99 Decreased By ▼ -0.13 (-0.52%)
TRG 57.81 Decreased By ▼ -0.23 (-0.4%)
UNITY 33.58 Decreased By ▼ -0.09 (-0.27%)
WTL 1.70 Decreased By ▼ -0.01 (-0.58%)
BR100 11,897 Increased By 6.6 (0.06%)
BR30 37,138 Decreased By -218.4 (-0.58%)
KSE100 110,625 Decreased By -445.2 (-0.4%)
KSE30 34,772 Decreased By -136.7 (-0.39%)

WASHINGTON: People who were exposed to Covid and received under-the-skin injections of Regeneron’s synthetic antibody treatment were 81 percent less likely to develop the disease compared to those on a placebo, the company said Monday.

The trial, which was jointly run with the US National Institutes of Health, enrolled 1,505 people with household contacts who had tested positive for Covid-19.

The volunteers themselves tested negative at the start of the trial, and were then randomly assigned to receive either one dose of REGEN-COV — which is a 1,200 milligram combination of asirivimab and imdevimab — or a placebo.

After 29 days, 1.5 percent of people who received the treatment developed symptomatic Covid, compared to 7.8 percent for those on placebo.

This equates to a risk reduction of 81 percent, which compares favorably with authorized Covid vaccines.

The participants were ethnically diverse, 31 percent had at least one risk factor, the median age was 44 years old and the age range was 12 to 92 years.

No one who received the treatment was hospitalized or had to go to an emergency room for Covid-19, while four who received the placebo did.

Side effects occurred in 20 percent of people on the drug and 29 percent on placebo, while serious side effects occurred in one percent of participants of both groups.—AFP

Comments

Comments are closed.